SCHEMBL13660746

SCHEMBL13660746

C[C@H]1CN(C(=O)OC(C)(C)C)CCN1C(=O)c1ccc(NC(=O)NC2CCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SETD7 Q8WTS6 2/20 0.55
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
USP30 Q70CQ3 1/20 0.51
ABL1 P00519 1/20 0.50
RIN1 Q13671 1/20 0.50
EPHX2 P34913 4/20 0.49
NPC1 O15118 3/20 0.48
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
FPR2 P25090 4/20 0.47
EPHX1 P07099 3/20 0.47
RAB9A P51151 1/20 0.45
NAMPT P43490 1/20 0.44
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
FPR3 P25089 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12954995 1.00 SETD7 (0.55) SETD7CA12CA1CA2CA9
SCHEMBL12955131 0.87 ABL1 (0.65) CA12CA1CA2CA9USP30
SCHEMBL1021985 0.86 EPHX1 (0.50) EPHX2NPC1ALDH1A1SMN1; SMN2EPHX1
SCHEMBL28878080 0.78 SETD7 (0.66) SETD7
SCHEMBL28878082 0.78 SETD7 (0.66) SETD7
SCHEMBL1102308 0.78 SETD7 (0.65) SETD7USP30
SCHEMBL3638878 0.78 SETD7 (0.65) SETD7USP30
SCHEMBL4008714 0.77 EPHX2 (0.69) CA12CA1CA2CA9ABL1
SCHEMBL19284223 0.77 SETD7 (0.67) SETD7ALDH1A1SMN1; SMN2
SCHEMBL4010884 0.76 CA12 (0.69) CA12CA1CA2CA9ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 SETD7 4434/4885CA12 4541/4885CA1 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.